Table 2. MSI findings for the epithelium and stroma, with reference to tumour features.
|
MSI+ cases /informative cases |
MSI+ cases/informative cases | ||||
|---|---|---|---|---|---|
| Variable | Total cases | Epithelium | Stroma | P-value | Mixed tissue |
| Location | |||||
| Right side | 14 | 6/14 (43%) | 7/14 (50%) | 0.3549 | 4/14 (29%) |
| Left side | 26 | 7/24 (29%) | 9/25 (36%) | 0.1388 | 5/26 (19%) |
| Differentiation | |||||
| Well | 14 | 2/13 (15%) | 7/13 (54%) | 0.0393* | 2/14 (14%) |
| Moderate | 16 | 6/15 (40%) | 8/16 (50%) | 0.5761 | 5/16 (31%) |
| Poor | 10 | 5/10 (50%) | 1/10 (10%) | 0.0510** | 2/10 (20%) |
| Dukes' stage | |||||
| A | 11 | 0/10 (0%) | 6/11 (55%) | 0.0057* | 1/11 (9%) |
| B | 12 | 6/12 (50%) | 5/12 (42%) | 0.6820 | 4/12 (33%) |
| C | 17 | 7/16 (44%) | 5/16 (31%) | 0.4652 | 4/17 (24%) |
| p53 mutation | |||||
| + | 15 | 4/13 (31%) | 5/14 (36%) | 0.7854 | 4/15 (27%) |
| − | 25 | 9/25 (36%) | 11/25 (44%) | 0.5637 | 5/25 (20%) |
| K-ras mutation | |||||
| + | 12 | 5/11 (45%) | 6/11 (55%) | 0.6698 | 4/12 (33%) |
| − | 28 | 8/27 (30%) | 10/27 (37%) | 0.6307 | 5/28 (18%) |
| p53 protein | |||||
| − | 7 | 1/7 (14%) | 3/7 (43%) | 0.5594 | 1/7 (14%) |
| + | 10 | 3/10 (30%) | 7/10 (70%) | 0.0943** | 3/10 (30%) |
| ++ | 23 | 9/21 (43%) | 6/22 (27%) | 0.5127 | 5/23 (22%) |
| hMLH1 protein | |||||
| − | 2/4 (50%)a | 1/1 (100%)b | |||
| + | 0/6 (0%) | 12/30 (40%) | |||
| ++ | 11/27 (40%) | 3/7 (43%) | |||
| hMSH2 protein | |||||
| − | 0/1 (0%)a | 0/0 (0%)b | |||
| + | 3/9 (33%) | 16/35 (46%) | |||
| ++ | 10/25 (40%) | 0/2 (50%) | |||
Significance was determined by the χ2 test and Fisher's exact test (epithelium vs stroma).‘MSI+ cases’ refer to cases that showed MSI+ for at least one marker.
*
P < 0.05
**
P < 0.1
a
n = The cases of hMLH1 or hMSH2 protein expression in epithelial cells.
b
n = The cases of hMLH1 or hMSH2 protein expression in stromal cells.